Literature DB >> 16306404

Neural activity controls the synaptic accumulation of alpha-synuclein.

Doris L Fortin1, Venu M Nemani, Susan M Voglmaier, Malcolm D Anthony, Timothy A Ryan, Robert H Edwards.   

Abstract

The presynaptic protein alpha-synuclein has a central role in Parkinson's disease (PD). However, the mechanism by which the protein contributes to neurodegeneration and its normal function remain unknown. Alpha-synuclein localizes to the nerve terminal and interacts with artificial membranes in vitro but binds weakly to native brain membranes. To characterize the membrane association of alpha-synuclein in living neurons, we used fluorescence recovery after photobleaching. Despite its enrichment at the synapse, alpha-synuclein is highly mobile, with rapid exchange between adjacent synapses. In addition, we find that alpha-synuclein disperses from the nerve terminal in response to neural activity. Dispersion depends on exocytosis, but unlike other synaptic vesicle proteins, alpha-synuclein dissociates from the synaptic vesicle membrane after fusion. Furthermore, the dispersion of alpha-synuclein is graded with respect to stimulus intensity. Neural activity thus controls the normal function of alpha-synuclein at the nerve terminal and may influence its role in PD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16306404      PMCID: PMC6725870          DOI: 10.1523/JNEUROSCI.2922-05.2005

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  113 in total

1.  Vesicular monoamine and glutamate transporters select distinct synaptic vesicle recycling pathways.

Authors:  Bibiana Onoa; Haiyan Li; Johann A Gagnon-Bartsch; Laura A B Elias; Robert H Edwards
Journal:  J Neurosci       Date:  2010-06-09       Impact factor: 6.167

2.  Biochemical and morphological consequences of human α-synuclein expression in a mouse α-synuclein null background.

Authors:  Kavita Prasad; Elizabeth Tarasewicz; Pamela A Ohman Strickland; Michael O'Neill; Stephen N Mitchell; Kalpana Merchant; Samnang Tep; Kathryn Hilton; Akash Datwani; Manuel Buttini; Sarah Mueller-Steiner; Eric K Richfield
Journal:  Eur J Neurosci       Date:  2011-01-28       Impact factor: 3.386

Review 3.  The physiological role of α-synuclein and its relationship to Parkinson's Disease.

Authors:  David Sulzer; Robert H Edwards
Journal:  J Neurochem       Date:  2019-07-28       Impact factor: 5.372

Review 4.  Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease.

Authors:  Seung-Jae Lee
Journal:  J Mol Neurosci       Date:  2007-04-17       Impact factor: 3.444

Review 5.  On the key role played by altered protein conformation in Parkinson's disease.

Authors:  L F Agnati; E Baldelli; N Andreoli; A S Woods; V Vellani; D Marcellino; D Guidolin; K Fuxe
Journal:  J Neural Transm (Vienna)       Date:  2008-06-05       Impact factor: 3.575

6.  Common key-signals in learning and neurodegeneration: focus on excito-amino acids, beta-amyloid peptides and alpha-synuclein.

Authors:  L F Agnati; G Leo; S Genedani; L Piron; A Rivera; D Guidolin; K Fuxe
Journal:  J Neural Transm (Vienna)       Date:  2008-11-19       Impact factor: 3.575

7.  Mitochondrial permeability transition pore regulates Parkinson's disease development in mutant α-synuclein transgenic mice.

Authors:  Lee J Martin; Samantha Semenkow; Allison Hanaford; Margaret Wong
Journal:  Neurobiol Aging       Date:  2013-11-16       Impact factor: 4.673

Review 8.  Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

Review 9.  Combination therapies: The next logical Step for the treatment of synucleinopathies?

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Mov Disord       Date:  2015-09-21       Impact factor: 10.338

Review 10.  Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.

Authors:  Elvira Valera; Brian Spencer; Eliezer Masliah
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.